Patents Assigned to Tumor Biology Investment Group
-
Patent number: 8017752Abstract: The present invention relates to the discovery of soluble isoforms of an Epidermal Growth Factor Receptor, or sErbB1 variants, the provision of the sequences of nucleic acids encoding these isoforms, purified recombinant proteins, novel antibodies specific for these isoforms, and the use of immunoassay and other protein assay techniques to measure the concentration of these protein isoforms in a patient biological sample in the femtomolar range. The present invention also provides methods for determining the presence of an ovarian carcinoma in the patient by assaying the concentration of soluble ErbB1 variants in a biological sample from a patient.Type: GrantFiled: March 25, 2010Date of Patent: September 13, 2011Assignee: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Jill Reiter
-
Patent number: 7892541Abstract: Embodiments of the present invention relate to p110 soluble EGFR (p110 sEGFR) peptides and nucleic acid sequences. Antibodies, methods of detection, kits, and expression vectors for p110 sEGFR are disclosed. In addition, assays on biological samples for determining and evaluating risk assessment and cancer prevention, screening and early detection, diagnosis, prognosis, theragnosis, monitoring of responsiveness to treatment, and monitoring of disease progression, recurrence, or metastasis of a cancer, are disclosed. In examples, a lower p110 sEGFR concentration adjusted for demographical and physiological variables and other biomarkers is associated with cancer. Therapeutics and methods of treating a cancer related to p110 sEGFR also are embodied herein.Type: GrantFiled: September 8, 2008Date of Patent: February 22, 2011Assignee: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Andre Baron, Jill Reiter
-
Patent number: 7745398Abstract: Regulation of sErbB3 isoforms in methods of regulating heregulin activity or ErbB receptor activities is disclosed. Cancer therapeutics and methods of therapeutically treating cancer comprising sErbB3 are also disclosed. Detection of sErbB3 in biological samples for risk assessment and prevention, screening, diagnosis, prognosis, theragnosis, evaluation of responsiveness to treatment, and/or monitoring of disease progression, recurrence, or metastasis of a cancer is disclosed as well. In examples, sErbB3 nucleic acid sequences, polypeptides, molecular probes, and antibodies are useful agents for regulation, expression, detection, and cancer therapeutics related to sErbB3.Type: GrantFiled: June 23, 2008Date of Patent: June 29, 2010Assignee: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Patent number: 7744882Abstract: Regulation of sErbB3 isoforms in methods of regulating heregulin activity or ErbB receptor activities is disclosed. Cancer therapeutics and methods of therapeutically treating cancer comprising sErbB3 are also disclosed. Detection of sErbB3 in biological samples for risk assessment and prevention, screening, diagnosis, prognosis, theragnosis, evaluation of responsiveness to treatment, and/or monitoring of disease progression, recurrence, or metastasis of a cancer is disclosed as well. In examples, sErbB3 nucleic acid sequences, polypeptides, molecular probes, and antibodies are useful agents for regulation, expression, detection, and cancer therapeutics related to sErbB3.Type: GrantFiled: June 23, 2008Date of Patent: June 29, 2010Assignee: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Patent number: 7732157Abstract: The present invention relates to the discovery of soluble isoforms of an Epidermal Growth Factor Receptor, or sErbB 1/HER1 variants, the provision of the sequences of nucleic acids encoding these isoforms, purified recombinant proteins, novel antibodies specific for these isoforms, and the use of immunoassay and gene expression assay techniques to measure the concentration of these gene products in a patient biological sample. The present invention also provides methods for determining the presence of an ovarian carcinoma in the patient by assaying the concentration of soluble EGFR/ErbB1 variants in a biological sample from a patient.Type: GrantFiled: September 29, 2000Date of Patent: June 8, 2010Assignee: Tumor Biology Investment GroupInventors: Andre T. Baron, Nita J. Maihle
-
Patent number: 7718384Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.Type: GrantFiled: June 20, 2008Date of Patent: May 18, 2010Assignee: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Patent number: 7638302Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.Type: GrantFiled: January 23, 2008Date of Patent: December 29, 2009Assignee: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Patent number: 7638303Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.Type: GrantFiled: June 23, 2008Date of Patent: December 29, 2009Assignee: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Patent number: 7612042Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.Type: GrantFiled: January 23, 2008Date of Patent: November 3, 2009Assignee: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Lee Hakjoo
-
Publication number: 20090017471Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.Type: ApplicationFiled: June 20, 2008Publication date: January 15, 2009Applicant: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Publication number: 20080274115Abstract: Regulation of sErbB3 isoforms in methods of regulating heregulin activity or ErbB receptor activities is disclosed. Cancer therapeutics and methods of therapeutically treating cancer comprising sErbB3 are also disclosed. Detection of sErbB3 in biological samples for risk assessment and prevention, screening, diagnosis, prognosis, theragnosis, evaluation of responsiveness to treatment, and/or monitoring of disease progression, recurrence, or metastasis of a cancer is disclosed as well. In examples, sErbB3 nucleic acid sequences, polypeptides, molecular probes, and antibodies are useful agents for regulation, expression, detection, and cancer therapeutics related to sErbB3.Type: ApplicationFiled: June 23, 2008Publication date: November 6, 2008Applicant: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Publication number: 20080274504Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.Type: ApplicationFiled: June 23, 2008Publication date: November 6, 2008Applicant: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Publication number: 20080267961Abstract: Regulation of sErbB3 isoforms in methods of regulating heregulin activity or ErbB receptor activities is disclosed. Cancer therapeutics and methods of therapeutically treating cancer comprising sErbB3 are also disclosed. Detection of sErbB3 in biological samples for risk assessment and prevention, screening, diagnosis, prognosis, theragnosis, evaluation of responsiveness to treatment, and/or monitoring of disease progression, recurrence, or metastasis of a cancer is disclosed as well. In examples, sErbB3 nucleic acid sequences, polypeptides, molecular probes, and antibodies are useful agents for regulation, expression, detection, and cancer therapeutics related to sErbB3.Type: ApplicationFiled: June 23, 2008Publication date: October 30, 2008Applicant: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Publication number: 20080261882Abstract: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.Type: ApplicationFiled: January 23, 2008Publication date: October 23, 2008Applicant: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Publication number: 20080261270Abstract: The present invention discloses a system and method using isoforms of the human ErbB3 receptor as negative regulators of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses a system and method of one such isoform, p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells and uses p85-sErbB3 as a negative regulator of heregulin-stimulated signal transduction and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of preparing the protein.Type: ApplicationFiled: January 23, 2008Publication date: October 23, 2008Applicant: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee
-
Patent number: 7390632Abstract: The present invention discloses a system and method using the human ErbB3 receptor, p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses a system and method of p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells and uses p85-sErbB3 as a negative regulator of heregulin-stimulated signal transduction and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of preparing the protein.Type: GrantFiled: May 31, 2002Date of Patent: June 24, 2008Assignee: Tumor Biology Investment Group, Inc.Inventors: Nita J. Maihle, Hakjoo Lee